European Journal of Clinical Pharmacology

, Volume 39, Issue 2, pp 173–176 | Cite as

Variation of benzbromarone elimination in man — a population study

  • I. Walter-Sack
  • U. Gresser
  • M. Adjan
  • I. Kamilli
  • A. Ittensohn
  • J. X. de Vries
  • E. Weber
  • N. Zöllner


The plasma benzbromarone concentration-time profile in a healthy subject who retained the compound much longer than other individuals is described. The data suggested that determination of the 24 h plasma concentration of the parent drug after a single oral dose of 100 mg benzbromarone would be an appropriate procedure to determine the elimination phenotype. Based on this procedure, 148 of 153 healthy individuals (97%) in a population study were found to eliminate benzbromarone rapidly. In one subject the 24 h benzbromarone plasma concentration was very similar to the that observed in the individual who had been more fully characterized. Four participants gave intermediate results. The data are compatible with a bimodal or trimodal distribution of different benzbromarone elimination phenotypes.

Key words

Benzbromarone elimination phenotype distribution drug metabolism drug polymorphism adverse reaction 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Broekhuysen J, Pacco M, Sion R, Demeulenaere L, van Hee M (1972) Metabolism of benzbromarone in man. Eur J Clin Pharmacol 4: 125–130Google Scholar
  2. 2.
    Yü T-F (1976) Pharmacokinetic and clinical studies of a new uricosuric agent — benzbromarone. J Rheumatol 3 305–312Google Scholar
  3. 3.
    Ferber H, Vergin H, Hitzenberger G (1981) Pharmacokinetics and biotransformation of benzbromarone in man. Eur J Clin Pharmacol 19: 431–435Google Scholar
  4. 4.
    Walter-Sack I, de Vries JX, Ittensohn A, Weber E (1987) Benzbromarone disposition following single dose application. Evidence for lack of debromination. Klin Wochenschr 65: [Suppl X]: 5Google Scholar
  5. 5.
    de Vries JX, Walter-Sack I, Löffler W (1987) The biotransformation of benzbromarone in humans. Characterisation of a new metabolite by gas chromatography mass spectrometry. Klin Wochenschr 65: [Suppl X]: 10Google Scholar
  6. 6.
    Walter-Sack I, de Vries JX, Ittensohn A, Kohlmeier M, Weber E (1988) Benzbromarone disposition and uricosuric action; evidence for hydroxylation instead of debromination to benzarone. Klin Wochenschr 66: 160–166Google Scholar
  7. 7.
    de Vries JX, Walter-Sack I, Ittensohn A, Weber E (1989) The isolation, identification and structure of a new hydroxylated metabolite of benzbromarone in man. Xenobiotica 19: 1461–1470Google Scholar
  8. 8.
    Walter-Sack I, Eichelbaum M, de Vries JX, Weber E (1988) Benzbromarone biotransformation is not related to polymorphic oxidation of sparteine. Klin Wochenschr 66: 1097–1098Google Scholar
  9. 9.
    de Vries JX, Walter-Sack I, Ittensohn A (1987) Analysis of benzbromarone in human plasma and urine by high-performance liquid chromatography and gas chromatography — mass spectrometry. J Chromatogr 417: 420–427Google Scholar
  10. 10.
    Ittensohn A, de Vries JX (1989) A simplified method for a quantitative determination of benzbromarone in human plasma by HPLC. Eur J Pharmacol 36: [Suppl]: A228Google Scholar
  11. 11.
    Eichelbaum M, Spannbrucker N, Steincke B, Dengler HJ (1979) Defective N-oxidation of sparteine in man: a new pharmacogenetic defect. Eur J Clin Pharmacol 16: 183–187Google Scholar
  12. 12.
    Eichelbaum M, Bertilsson L, Säwe J, Zekorn C (1982) Polymorphic oxidation of sparteine and debrisoquine: related pharmacogenetic entities. Clin Pharmacol Ther 31: 184–186Google Scholar
  13. 13.
    Eichelbaum M, Bertilsson L, Säwe J (1983) Antipyrine metabolism in relation to polymorphic oxidations of sparteine and debrisoquine. Br J Clin Pharmacol 15: 317–321Google Scholar
  14. 14.
    Mahgoub A, Idle JR, Dring LG, Lancaster R, Smith RL (1977) Polymorphic hydroxylation of debrisoquine in man. Lancet II: 584–586Google Scholar
  15. 15.
    Tucker GT, Silas JH, Iyun AO, Lennard MS, Smith AJ (1977) Polymorphic hydroxylation of debrisoquine. Lancet II: 718Google Scholar
  16. 16.
    Lennard MS, Freestone S, Ramsay LE, Tucker GT, Woods HF (1983) Oxidation phenotype and betablockers. N Engl J Med 308: 965–966Google Scholar
  17. 17.
    Eichelbaum M (1988) Genetic polymorphism of sparteine/debrisoquine oxidation. ISI Atlas of science: pharmacology. Institute for Scientific Information, Philadelphia, pp 243–250Google Scholar
  18. 18.
    Zöllner N, Gresser U, Walter-Sack I (1990) Deficient benzbromarone elimination: a familial disorder? Klin Wochenschr 68: 101Google Scholar
  19. 19.
    Dengler HJ, Eichelbaum M (1977) Polymorphismen und Defekte des Arzneimittelstoffwechsels als Ursache toxischer Reaktionen. Arzneim Forsch/Drug Res 27: 1836–1844Google Scholar
  20. 20.
    Eichelbaum M (1982) Defective oxidation of drugs: pharmacokinetic and therapeutic implications. Clin Pharmacokinet 7: 1–22Google Scholar
  21. 21.
    Lennard MS, Tucker GT, Woods HF (1986) The polymorphic oxidation of β-adrenoceptor antagonists. Clinical pharmacokinetic considerations. Clin Pharmacokinet 11: 1–17Google Scholar
  22. 22.
    Zöllner N, Dofel W, Gröbner W (1970) Die Wirkung von Benzbromaronum auf die renale Harnsäureausscheidung Gesunder. Klin Wochenschr 48: 426–432Google Scholar
  23. 23.
    Bonn R, Chasseaud LF, Grote H, John BA, Sandrock K, Wood SG (dy1986) Biotransformation of benzarone in man. Naunyn-Schmiedeberg's Arch Pharmacol 334: [Suppl]: R12Google Scholar
  24. 24.
    Walter-Sack I (1989) Recent advances in uricosuric drug research. Ann Nutr Metab 33: 203Google Scholar

Copyright information

© Springer-Verlag 1990

Authors and Affiliations

  • I. Walter-Sack
    • 1
  • U. Gresser
    • 2
  • M. Adjan
    • 2
  • I. Kamilli
    • 2
  • A. Ittensohn
    • 1
  • J. X. de Vries
    • 1
  • E. Weber
    • 1
  • N. Zöllner
    • 2
  1. 1.Abteilung Klinische Pharmakologie der Medizinischen KlinikUniversität HeidelbergFRG
  2. 2.Medizinische PoliklinikLudwig-Maximilians-UniversitätMünchenFRG

Personalised recommendations